Once			O
-			O
daily			O
(			O
QD			O
)			O
fosamprenavir			O
(			O
FPV			O
)			O
at			O
1,400			O
mg			O
boosted			O
with			O
low			O
-			O
dose			O
ritonavir			O
(			O
RTV			O
)			O
at			O
200			O
mg			O
is			O
effective			O
when			O
it			O
is			O
used			O
in			O
combination			O
regimens			O
for			O
the			O
initial			O
treatment			O
of			O
human			O
immunodeficiency			O
virus			O
infection			O
.			O


Whether			O
a			O
lower			O
RTV			O
boosting			O
dose			O
(			O
i.e.			O
,			O
100			O
mg			O
QD			O
)			O
could			O
ensure			O
sufficient			O
amprenavir			O
(			O
APV			O
)			O
concentrations			O
with			O
improved			O
safety			O
/			O
tolerability			O
is			O
unknown			O
.			O


This			O
randomized			O
,			O
two			O
14			O
-			O
day			O
-			O
period			O
,			O
crossover			O
pharmacokinetic			O
study			O
compared			O
the			O
steady			O
-			O
state			O
plasma			O
APV			O
concentrations			O
,			O
safety			O
,			O
and			O
tolerability			O
of			O
FPV			O
at			O
1			O
,			O
400			O
mg			O
QD			O
boosted			O
with			O
either			O
100			O
mg			O
or			O
200			O
mg			O
of			O
RTV			O
QD			O
in			O
36			O
healthy			O
volunteers			O
.			O


Geometric			O
least			O
-			O
square			O
(			O
GLS			O
)			O
mean			O
ratios			O
and			O
the			O
associated			O
90			O
%			O
confidence			O
intervals			O
(			O
CIs			O
)			O
were			O
estimated			O
for			O
plasma			O
APV			O
maximum			O
plasma			O
concentrations			O
(			O
Cmax			O
)			O
,			O
the			O
area			O
under			O
the			O
plasma			O
concentration			O
-			O
time			O
curve			O
over			O
the			O
dosing			O
period			O
(			O
AUC0			O
-			O
tau			O
)			O
,			O
and			O
trough			O
concentrations			O
(			O
Ctau			O
)			O
during			O
each			O
dosing			O
period			O
.			O


Equivalence			O
between			O
regimens			O
(			O
90			O
%			O
CIs			O
of			O
GLS			O
mean			O
ratios			O
,			O
0.80			O
to			O
1.25			O
)			O
was			O
observed			O
for			O
the			O
plasma			O
APV			O
AUC0			O
-			O
tau			O
(			O
GLS			O
mean			O
ratio			O
,			O
0.90			O
[			O
90			O
%			O
CI			O
,			O
0.84			O
to			O
0.96			O
]			O
)			O
and			O
Cmax			O
(			O
0.97			O
[			O
90			O
%			O
CI			O
,			O
0.91			O
to			O
1.04			O
]			O
)			O
.			O


The			O
APV			O
Ctau			O
was			O
38			O
%			O
lower			O
with			O
RTV			O
at			O
100			O
mg			O
QD			O
than			O
with			O
RTV			O
at			O
200			O
mg			O
QD			O
(			O
GLS			O
mean			O
ratio			O
,			O
0.62			O
[			O
90			O
%			O
CI			O
,			O
0.55			O
to			O
0.69			O
]			O
)			O
but			O
remained			O
sixfold			O
higher			O
than			O
the			O
protein			O
-			O
corrected			O
50			O
%			O
inhibitory			O
concentration			O
for			O
wild			O
-			O
type			O
virus			O
,			O
with			O
the			O
lowest			O
APV			O
Ctau			O
observed			O
during			O
the			O
100			O
-			O
mg			O
QD			O
period			O
being			O
nearly			O
threefold			O
higher			O
.			O


The			O
GLS			O
mean			O
APV			O
Ctau			O
was			O
2.5			O
times			O
higher			O
than			O
the			O
historical			O
Ctau			O
for			O
unboosted			O
FPV			O
at			O
1,400			O
mg			O
twice			O
daily			O
.			O


Fewer			O
clinical			O
adverse			O
drug			O
events			O
and			O
smaller			O
increases			O
in			O
triglyceride			O
levels			O
were			O
observed			O
with			O
the			O
RTV			O
100			O
-			O
mg			O
QD			O
regimen			O
.			O


Clinical			O
trials			O
evaluating			O
the			O
efficacy			O
and			O
safety			O
of			O
FPV			O
at			O
1			O
,			O
400			O
mg			O
QD			O
boosted			O
by			O
RTV			O
at			O
100			O
mg			O
QD			O
are			O
now			O
under			O
way			O
with			O
antiretroviral			O
therapy			O
-			O
na√Øve			O
patients			O
.			O
